Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Seetharamu on Current Platforms Utilized for Molecular Testing in Lung Cancer

September 17th 2024

Nagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

September 17th 2024

The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.

Several IO Combos Miss Efficacy Target in NSCLC, But Clinical Benefit Seen With 2 Combos

September 16th 2024

Durvalumab plus monalizumab and durvalumab plus ceralasertib showed promising long-term benefits in advanced NSCLC.

Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC

September 16th 2024

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Perioperative Nivolumab Shows EFS Benefit vs Placebo in Resectable NSCLC

September 15th 2024

Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.

TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors

September 15th 2024

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC

September 14th 2024

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Zipalertinib Demonstrates Safety, Disease Control in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Zipalertinib demonstrates safety and efficacy in heavily pretreated patients with NSCLC EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Encorafenib/Binimetinib Exhibits Anti-Tumor Activity in Untreated BRAF-Mutant Advanced NSCLC

September 14th 2024

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

Low-Dose Pembrolizumab May Prove Equal Efficacy as a Standard Dose for Stage IV NSCLC

September 14th 2024

A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.

NVL-655 Shows Strong Efficacy in Heavily Pretreated ALK+ NSCLC

September 14th 2024

The novel ALK inhibitor NVL-655 demonstrated encouraging activity in heavily pretreated patients with advanced ALK-positive NSCLC.

Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

September 14th 2024

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.

Longer Follow-Up Confirms Superior Outcomes With Amivantamab Plus Chemo in EGFR-Mutant Advanced NSCLC

September 14th 2024

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC

September 14th 2024

Treatment with belrestotug plus dostarlimab yielded a clinically meaningful improvement in ORR vs dostarlimab monotherapy in unresectable PD-L1–high NSCLC.

Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC

September 13th 2024

BMS-986012 plus nivolumab and chemotherapy provided a modest PFS benefit but signals of OS improvement in extensive-stage small cell lung cancer.

Consolidation Durvalumab Shows Consistent Survival Benefit in LS-SCLC Regardless of Prior PCI and CRT Components

September 13th 2024

Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.

Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status

September 13th 2024

Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

September 12th 2024

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

Plinabulin Plus Docetaxel Boosts OS in Pretreated EGFR Wild-Type NSCLC

September 12th 2024

The DUBLIN-3 trial showed plinabulin plus docetaxel improved survival in EGFR wild-type non–small cell lung cancer.

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

September 11th 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.